PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1384148-2	1992	In a phase II study using ifosfamide in combination with cisplatin/bleomycin (BIP) in advanced and recurrent cervical cancer, we demonstrated a response rate of 69%.	Bleomycin	67-76	heat shock protein family A (Hsp70) member 5	Homo sapiens	78-81	
2468183-1	1989	A series of phase II studies using ifosfamide as a single agent and in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer were coordinated at the West Midlands Cancer Research Campaign Clinical Trials Unit, Birmingham, UK.	Bleomycin	102-111	heat shock protein family A (Hsp70) member 5	Homo sapiens	113-116	
29705800-8	2018	Meanwhile, GRP78 was upregulated in A549 cells exposed to tunicamycin or bleomycin.	Bleomycin	73-82	heat shock protein family A (Hsp70) member 5	Homo sapiens	11-16	
29079731-7	2017	We demonstrated that bleomycin can activate ER stress associated proteins, including GRP78, CHOP, and ATF-4, both in vitro and in vivo.	Bleomycin	21-30	heat shock protein family A (Hsp70) member 5	Homo sapiens	85-90	
2462439-1	1988	We report the results of phase II studies using a combination of ifosfamide, cis-platinum and bleomycin (BIP) in advanced and recurrent cervical cancer.	Bleomycin	94-103	heat shock protein family A (Hsp70) member 5	Homo sapiens	105-108	
6174228-2	1982	This report gives the results of assays of sera from patients for the bleomycin inhibitor protein (BIP) using the Pseudomonas bacteriophage covalently closed circular DNA fluorescence technique standardized for DNA breakage induced by bleomycin.	Bleomycin	70-79	heat shock protein family A (Hsp70) member 5	Homo sapiens	99-102	
24148527-3	2013	In patients with mild or moderate BIP, radiological signs disappear almost completely within nine months after discontinuation of bleomycin treatment.	Bleomycin	130-139	heat shock protein family A (Hsp70) member 5	Homo sapiens	34-37	
1693314-1	1990	A series of phase II studies using ifosfamide (IFX) as a single agent and in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer have been coordinated at the West Midlands CRC Clinical Trials Unit (Birmingham, UK).	Bleomycin	108-117	heat shock protein family A (Hsp70) member 5	Homo sapiens	119-122	
1693316-2	1990	In a phase II study, coordinated at the West Midlands CRC Clinical Trials Unit, Birmingham, using ifosfamide (IFX) in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer, we demonstrated a response rate of 69%.	Bleomycin	149-158	heat shock protein family A (Hsp70) member 5	Homo sapiens	160-163